AMADIS
28.3.2022 07:02:12 CEST | Business Wire | Press release
PayPlug (part of the Payment activities of Groupe BPCE ) selects Amadis , a global payment software editor, to deploy its nexo based payment acceptance application, on an array of traditional payment terminals and Android SoftPOS devices, through a standardized payment acceptance approach, independent of EMV® Level 2 card processing frameworks. This drastically reduces deployment times, maintenance costs, and provides PayPlug with ownership over its card acceptance solutions. The alliance builds on the long-standing partnership between Amadis and PayPlug.
PayPlug’s new application enables every store associate to bring the check out experience to the customer, the POI (point of interaction), wherever the consumer needs it to be, by enabling Android NFC COTS (Commercial-Off-The-Shelf) devices, such as smartphones, tablets or professional dedicated instruments.
“Amadis provided us with an effective way to offer our SME customers with innovative, new ways to accept card-present payments,” said Antoine Grimaud, PayPlug CEO. “We expect the solution to drive new revenue opportunities for our customers, while generating new points of payment acceptance in multiple countries, and enhancing the customer experience.
PayPlug’s new application includes all components of Amadis One (Amadis’ SoftPOS solution), in particular OLA (Open Level 2 API). OLA is an abstraction layer that allows an enterprise to run a payment application with the EMV Level 2 stack of any terminal manufacturer or SoftPOS - allowing enterprises to be fully payment device agnostic, independent of ecosystem, hardware and operating system.
“The new PayPlug application represents a new era for payments acceptance, and we are excited to be a part of their solution,” said Emmanuel Haydont, Amadis CEO. “With nexo protocols a reality for customers, Amadis simplifies nexo deployments and reduces costs, while helping enterprises accelerate deployments and access to multiple countries.”
“We are delighted to see PayPlug, and its customers, become the latest company that will benefit from our standardization work,” explains Jacques Soussana, nexo standards Secretary-General. “Our specifications and protocols remove the barriers traditionally present in the payment acceptance ecosystem, including within non-traditional environments such as mobile acceptance platforms like smartphones, tablets and COTS.”
To make the solution more interoperable, PayPlug’s application needed to effectively integrate with nexo payment standards. Amadis simplified implementation with its open, standards-based off-the-shelf framework that is nexo compliant.
About PayPlug
PayPlug is the French omnichannel pay-by-card solution for SMEs. Since 2012, it has been offering an innovative and easy to use alternative to traditional market players: among other things, the fintech relies on its unique ecosystem of partners and integrated features to simplify all things related to payments for its 15,000 customers, retailers and e-merchants in Europe. After acquiring the status of Payment Institution approved by the ACPR Banque de France, PayPlug joined the BPCE group in April 2017. Over the last three years, PayPlug has experienced nearly 100% growth per year. www.payplug.com
About nexo standards
nexo standards is the association dedicated to removing the barriers present in today’s fragmented global payment acceptance ecosystem. It enables fast, borderless and global payments acceptance by standardizing the exchange of data between all payment acceptance stakeholders. The nexo specifications and messaging protocols adhere to ISO 20022 standards, are universally applicable and fully open. www.nexo-standards.org/
About Amadis
Amadis is a leader in compliant payment software technology, with its software running on more than 40 million devices worldwide. The company provides state-of-the-art software editing and development solutions for global merchants, payment device manufacturers and service providers. Amadis provides merchants with the industry’s broadest range of payment acceptance software technology options based on the most efficient available standards, independent of hardware, retail vertical segment, or geography. The company brings an elite, experienced software team to the industry and enables solutions for international fintech, processors and merchants in over 23 countries. Learn more at www.amadis.ca .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220327005013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom